Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Protagonist - What They Never Told You

Johnson & Johnson's M&A Strategy Is the Real Story for Investors

Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.

MarketBeat · Oct 18, 2025

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

Johnson Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).

Benzinga · Oct 10, 2025

Protagonist Therapeutics Earns $25M Milestone Payment From Janssen Biotech

Protagonist Therapeutics Earns $25M Milestone Payment From Janssen Biotech

Protagonist Therapeutics (NASDAQ:PTGX) has received a $25 million milestone payment from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE:JNJ). The payment comes after the dosing of the third patient in the Phase 2b FRONTIER 1 clinical trial of PN-235 (JNJ-77242113). FRONTIER 1 is a Phase 2b dose-ranging study to evaluate the…

Benzinga · Mar 16, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1

Coverage From

Organisations

Johnson & Johnson (

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

420,393 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play